益生菌对危重症患者呼吸机相关性肺炎发生率的影响:一项随机临床试验
该随机安慰剂对照试验在加拿大、美国和沙特阿拉伯的44个ICU纳入2653例预计机械通气至少72小时的成人患者,评估肠内给予鼠李糖乳杆菌GG(L rhamnosus GG)对呼吸机相关性肺炎(VAP)的预防效果。结果显示,益生菌组VAP发生率为21.9%,对照组为21.3%(HR 1.03,95%CI 0.87-1.22;益生菌组发生鼠李糖乳杆菌相关不良事件的比例更高(1.1% vs 0.1%)。结论不支持在危重症患者中使用L rhamnosus GG。
要点
- 20项预设次要结局(包括其他ICU获得性感染、腹泻、抗菌药物使用、死亡和住院时间)均无显著差异。
- 益生菌组鼠李糖乳杆菌相关不良事件发生率显著高于对照组(1.1% vs 0.1%,OR 14.02)。
核心结论
- 在需要机械通气的危重症患者中,与安慰剂相比,给予益生菌L rhamnosus GG并未显著降低VAP发生率。
- 研究结果不支持在危重症患者中使用L rhamnosus GG。
研究设计与样本
- 随机安慰剂对照试验,在加拿大、美国和沙特阿拉伯的44个ICU进行。
- 纳入2653例预计需要机械通气至少72小时的成人患者,从2013年10月至2019年3月入组(最终随访至2020年10月)。
- 干预为肠内L rhamnosus GG(1×10^10 CFU)或安慰剂,每日两次,在ICU内给药。
主要发现
- 20项预设次要结局(包括其他ICU获得性感染、腹泻、抗菌药物使用、死亡和住院时间)均无显著差异。
临床怎么用
- 对于需要机械通气的危重症患者,不应常规使用L rhamnosus GG来预防VAP。
- 临床决策时应权衡益生菌相关感染风险,尤其是鼠李糖乳杆菌在无菌部位或作为优势菌检出的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modification with probiotics. Prior randomized trials in this population suggest that probiotics reduce infection, particularly ventilator-associated pneumonia (VAP), although probiotic-associated infections have also been reported. OBJECTIVE: To evaluate the effect of Lactobacillus rhamnosus GG on preventing VAP, additional infections, and other clinically important outcomes in the intensive care unit (ICU). DESIGN, SETTING, AND PARTICIPANTS: Randomized placebo-controlled trial in 44 ICUs in Canada, the United States, and Saudi Arabia enrolling adults predicted to require mechanical ventilation for at least 72 hours. A total of 2653 patients were enrolled from October 2013 to March 2019 (final follow-up, October 2020). INTERVENTIONS: Enteral L rhamnosus GG (1 × 1010 colony-forming units) (n = 1321) or placebo (n = 1332) twice daily in the ICU. MAIN OUTCOMES AND MEASURES: The primary outcome was VAP determined by duplicate blinded central adjudication. Secondary outcomes were other ICU-acquired infections including Clostridioides difficile infection, diarrhea, antimicrobial use, ICU and hospital length of stay, and mortality. RESULTS: Among 2653 randomized patients (mean age, 59.8 years [SD], 16.5 years), 2650 (99.9%) completed the trial (mean age, 59.8 years [SD], 16.5 years; 1063 women [40.1%.] with a mean Acute Physiology and Chronic Health Evaluation II score of 22.0 (SD, 7.8) and received the study product for a median of 9 days (IQR, 5-15 days). VAP developed among 289 of 1318 patients (21.9%) receiving probiotics vs 284 of 1332 controls (21.3%; hazard ratio [HR], 1.03 (95% CI, 0.87-1.22; P = .73, absolute difference, 0.6%, 95% CI, -2.5% to 3.7%). None of the 20 prespecified secondary outcomes, including other ICU-acquired infections, diarrhea, antimicrobial use, mortality, or length of stay showed a significant difference. Fifteen patients (1.1%) receiving probiotics vs 1 (0.1%) in the control group experienced the adverse event of L rhamnosus in a sterile site or the sole or predominant organism in a nonsterile site (odds ratio, 14.02; 95% CI, 1.79-109.58; P < .001). CONCLUSIONS AND RELEVANCE: Among critically ill patients requiring mechanical ventilation, administration of the probiotic L rhamnosus GG compared with placebo, resulted in no significant difference in the development of ventilator-associated pneumonia. These findings do not support the use of L rhamnosus GG in critically ill patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02462590.
引用
- Johnstone J, Meade M, Lauzier F, et al. Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial. JAMA. 2021. PMID: 34546300. doi:10.1001/jama.2021.13355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。